The result adds nemvaleukin to a growing list of IL-2 candidates that have fallen short in trials, following high-profile disappointments such as Nektar Therapeutics and Bristol Myers Squibb’s ...

On Friday, Jefferies analyst Roger Song upgraded Nektar Therapeutics (NASDAQ:NKTR) stock from Hold to Buy, doubling the price target from $1.00 to $2.00. The decision comes as Nektar prepares to ...

Fintel reports that on April 11, 2025, Jefferies upgraded their outlook for Nektar Therapeutics (BMV:NKTR) from Hold to Buy. There are 549 funds or institutions reporting positions in Nektar ...

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It ...

Four years ago, Bristol-Myers Squibb paid $1.85 billion upfront to claim rights to Nektar's bempegaldesleukin, setting it up to be companion drug to its cancer immunotherapy Opdivo. Now ...